<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940641</url>
  </required_header>
  <id_info>
    <org_study_id>D1140C00017</org_study_id>
    <nct_id>NCT00940641</nct_id>
  </id_info>
  <brief_title>Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration</brief_title>
  <official_title>A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the absorption, distribution, metabolism and
      excretion of AZD7325 after intravenous and 14C labeled oral dose
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess absorption, distribution, metabolism and excretion of AZD7325 after IV dose and 14C oral dose administration</measure>
    <time_frame>Daily</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability after a single oral administration of [14C] AZD7325 and after a single intravenous administration of non radio-labelled AZD7325</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Absorption</condition>
  <condition>Distribution</condition>
  <condition>Metabolism</condition>
  <condition>Excretion</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose of AZD7325</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14C oral dose of AZD7325</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325</intervention_name>
    <description>IV Dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325</intervention_name>
    <description>oral dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects Day 1

          -  Body Mass Index (BMI) &gt; 18 and &lt; 30kg/m2

        Exclusion Criteria:

          -  Clinically relevant disease and abnormalities (past or present) which in the opinion
             of the investigator, may either put the subject at risk to participate in this study
             or may influence the results of the study or the subject's ability to participate in
             the study

          -  Use of prescription medication within 14 days of the first dose of the investigational
             product

          -  Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90
             days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood
             products within 14 days of Day -1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Chetty, MBBS, MD, FRCPath.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Alderly Park CPU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alderley Park</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Raj Tummala, M.D./MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

